biotech · Chronic Peripheral Neuropathy Pain in Diabetics · Diabetic Peripheral Neuropathy · XTLB
XTL BIOPHARMACEUTICALS
XTL BIOPHARMACEUTICALS LTD
XTL BIOPHARMACEUTICALS patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Raanana, USA
- Founded
- 1993
- Employees
- 3
- Programs
- 4
- Drugs
- 1
- Patents
- 7
XTL BIOPHARMACEUTICALS patents
7 pharmaceutical patents indexed for XTL BIOPHARMACEUTICALS. 0 expire within 24 months.
XTL BIOPHARMACEUTICALS has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 8329703
Pyrazole compounds
granted -
US 8143276
4-thio substituted quinoline and naphthyridine compounds
granted -
US 8048889
3,4-disubstituted coumarin and quinolone compounds
granted -
US 7994360
Benzofuran compounds
granted -
US 7923004
4-ethynyl pyrazole derivative compounds and methods for treatment of HCV
granted -
US 6254867
Human monoclonal antibodies to the hepatitis B surface antigen
expired -
US 6146629
Human monoclonal antibody against Hepatitis B virus surface antigen (HBVsAg)
expired
Frequently asked questions
How many patents does XTL BIOPHARMACEUTICALS have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do XTL BIOPHARMACEUTICALS patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.